BC Week In Review | Aug 19, 2013
Company News

Afraxis, Dainippon Sumitomo deal

Afraxis and Dainippon's Sunovion Pharmaceuticals Inc. subsidiary partnered to use Afraxis' Enhanced Spine Platform (ESP) to accelerate Sunovion's preclinical CNS drug discovery process. ESP uses measurement methods for protrusions on neuronal dendrites called dendritic spines...
BC Week In Review | May 13, 2013
Company News

Afraxis, Servier deal

The partners will use Afraxis' Enhanced Spine Platform (ESP) technology to discover treatments for CNS disorders. Afraxis' EPS technology evaluates the preclinical safety and efficacy of CNS compounds by quantifying and characterizing the morphology and...
BioCentury | Apr 22, 2013
Emerging Company Profile

Cardiorentis: Keeping heart

Cardiorentis AG is the fifth company to take on development of ularitide for acute heart failure. Armed with more than €100 million ($129.9 million) from undisclosed investors and expecting to have to do a smaller...
BC Innovations | May 27, 2010
Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Staphylococcus Staphylococcus epidermis extracellular serine proteinase (Esp) In vitro studies suggest that Esp secreted by S. epidermidis could help prevent S. aureus infection. In...
BC Innovations | Jan 29, 2009
Distillery Techniques

Technology: Computational models

This week in techniques Approach Summary Licensing status Publication and contact information Computational models Enhanced signature peptide (ESP) predictor to aid in assay development and biomarker validation The ESP predictor, a computational method based on...
BioCentury | May 12, 2008

Fentora risk management

Fentora risk management Mitigating risk of abuse and diversion Strategy Tactics Controlled exposure • At launch, Cephalon to limit face-to-face detailing to current Fentora prescribers (~6,000) • After one year, assess safety and surveillance information...
BioCentury | May 12, 2008

Fentora conundrum

Regulation Fentora conundrum By Peter A. Rittenhouse Senior Editor In voting not to recommend approval of Fentora for an expanded indication last week, an FDA advisory panel has put the agency in a bind if...
BioCentury | Mar 17, 2008

Ebb & Flow

Amgen investors were initially relieved after Thursday's votes by FDA's Oncologic Drugs Advisory Committee not to remove chemotherapy-induced anemia from the labels of erythropoiesis-stimulating agents. The stock closed the day up $2.19 to $47.18. But...
BC Extra | Mar 11, 2008
Financial News

EKR raises $145 million

EKR (Cedar Knolls, N.J.) raised $50 million in a series D round and secured $95 million in senior debt from GE Healthcare. The equity round was led by new investors MPM Capital and LLR Partners,...
BC Week In Review | Feb 11, 2008
Company News

EKR, PDL BioPharma deal

PDL will sell its cardiovascular assets to EKR for $85 million in cash up front, plus up to $85 million in milestones. The deal includes three marketed products that had 12-month sales of $165.5 million...
Items per page:
1 - 10 of 79